Exenatide · source year
5 selected, source-linked Exenatide records carrying a 2024 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
5 selected records.
2 represented types.
5 distinct public records.
Cited chronology
Regulatory
DailyMed lists Structured Product Labeling version 11 for the reviewed Exenatide label family with a published date of 2024-11-25. PeptideScanner retained the exact versioned ZIP byte count and SHA-256 receipt without republishing its contents.
Regulatory
The official Drugs@FDA dataset lists original submission 1 for ANDA 206697 with status AP dated 2024-11-19, and names exenatide synthetic among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Regulatory
The Federal Register published notice 2024-18898, attributed to FDA and its parent HHS department, on 2024-08-23. Its official title is “Final Decision on the Proposal To Refuse To Approve a New Drug Application for ITCA 650,” and PeptideScanner's exact reviewed identity mapping connects the document to Exenatide and Glucagon.
Source: Federal Register via GovInfo ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT02157974 at 2026-07-30T18:43:56.184Z. Its registry update date was 2024-06-04, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT04909333 at 2026-07-30T18:45:10.887Z. Its registry update date was 2024-05-08, and PeptideScanner's reviewed identity mapping was exenatide.
Source: ClinicalTrials.gov ↗